Diagnosing Pathologic Complete Response in the Breast After Neoadjuvant Systemic Treatment of Breast Cancer Patients by Minimal Invasive Biopsy-Reference-Cited by-同舟云学术

Diagnosing Pathologic Complete Response in the Breast After Neoadjuvant Systemic Treatment of Breast Cancer Patients by Minimal Invasive Biopsy

Published:2020-07-09 Issue:3 Volume:275 Page:576-581
ISSN:0003-4932
Container-title:Annals of Surgery
language:en
Short-container-title:

Author:

Heil Joerg,Pfob André,Sinn Hans-Peter,Rauch Geraldine,Bach Paul,Thomas Bettina,Schaefgen Benedikt,Kuemmel Sherko,Reimer Toralf,Hahn Markus,Thill Marc,Blohmer Jens-Uwe,Hackmann John,Malter Wolfram,Bekes Inga,Friedrichs Kay,Wojcinski Sebastian,Joos Sylvie,Paepke Stefan,Ditsch Nina,Rody Achim,Große Regina,van Mackelenbergh Marion,Reinisch Mattea,Karsten Maria,Golatta Michael,

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Surgery

Reference41 articles.

1. Neoadjuvant chemotherapy use in breast cancer is greatest in excellent responders: triple-negative and HER2+ subtypes;Murphy;Ann Surg Oncol,2018

2. Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial;van Ramshorst;Lancet Oncol,2018

3. Triple negative breast cancer subtypes and pathologic complete response rate to neoadjuvant chemotherapy;Santonja;Oncotarget,2018

4. Response rates and pathologic complete response by breast cancer molecular subtype following neoadjuvant chemotherapy;Haque;Breast Cancer Res Treat,2018

5. Clinical tumor stage is the most important predictor of pathological complete response rate after neoadjuvant chemotherapy in breast cancer patients;Goorts;Breast Cancer Res Treat,2017

Cited by 41 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The role of mesenchymal stem cells in cancer and prospects for their use in cancer therapeutics;MedComm;2024-07-28

2. Utility of Axillary Staging in Older Patients with HER2-Positive Breast Cancer;Annals of Surgical Oncology;2024-07-16

3. Clinical applications of next‐generation sequencing‐based ctDNA analyses in breast cancer: defining treatment targets and dynamic changes during disease progression;Molecular Oncology;2024-06-12

4. Omission of Breast Surgery in Exceptional Responders;Clinical Breast Cancer;2024-06

5. A nomogram for predicting pathologic node negativity after neoadjuvant chemotherapy in breast cancer patients: a nationwide, multicenter retrospective cohort study (CSBrS-012);Frontiers in Oncology;2024-05-10